Table 1—

Baseline characteristics and metabolic parameters of IGTN study participants

Baseline1 yearSignificance
Age (years)60 ± 8.4
Duration of neuropathy symptoms (months)7 ± 31
Exercise (min/week)80 ± 73
Sex
    Female20
    Male20
Metabolic features
    BMI (kg/m2)32.1 ± 4.431.0 ± 4.4P < 0.001
    Fasting plasma glucose (mg/dl)103 ± 13104 ± 12P < 0.7
    2-h glucose (mg/dl)160 ± 26149 ± 41P < 0.05
    Cholesterol
        Total200 ± 31190 ± 33P < 0.01
        LDL113 ± 2797.9 ± 40P < 0.06
        HDL49.6 ± 1354.1 ± 15P < 0.06
        Triglycerides237 ± 174196 ± 156P < 0.7
        Systolic blood pressure (mmHg)129 ± 13125 ± 14P < 0.12
        Diastolic blood pressure (mmHg)80.7 ± 8.677.7 ± 6.2P < 0.10
n with other microvascular complications
    Retinopathy0
    Microalbuminuria4
  • Data are means ± SD. Five subjects with IGT were included on the basis of isolated IFG (mean fasting plasma glucose 117 [range 112–125]). At 1 year, three of these five had IGT. Over the 1st year there was significant improvement in BMI, OGTT, and total cholesterol, with a trend toward improvement of LDL and HDL cholesterol. Retinal photography and assessment for microalbuminuria occurred at baseline only.